Adult

Cefoxitin

Warning

General Information

Do NOT use if patient has a history of severe penicillin allergy.  If in doubt, discuss with Micro/ID.

Restricted formulary antimicrobial: For details see OUH netFormulary

AWaRe antibiotic classification: 'Watch'. Use as per guidelines. All other indications to be discussed with Micro/ID.

Standard dose

  Intravenous dose
Standard dose

2g every 4-6 hours;

maximum 12g per day

Obesity

No dose adjustment required

Renal and hepatic impairment

Renal impairment

Creatinine clearance (ml/min)*

Dose

30-50

2g every 8-12 hours

10-29

2g every 12-24 hours

5-9

2g loading dose then 500mg-1g every 12-24 hours

Less than 5

2g loading dose then 500mg-1g every 24-48 hours

HD/HDF

2g every 24 hours

Dialysed; give after dialysis

PD

1g every 24 hours

Not dialysed

*dose ranges use creatinine clearance, rather than eGFR

 

Hepatic impairment

No dose adjustment required

Notable interactions

  • Warfarin – Rare cases of bleeding have been reported. Monitor INR closely, particularly within 3 days of starting or stopping cefoxitin.

This is not a complete list. Please see the BNF, Summary of Product Characteristics or speak to a pharmacist.

Pregnancy and breastfeeding

Pregnancy

Use only if benefit outweigh the risks


Breastfeeding

Discuss with pharmacy

Additional information

  • Renal function should be monitored during treatment if cefoxitin is given in combination with other potentially nephrotoxic antibiotics (especially aminoglycosides), or with furosemide or etacrynic acid diuretics.

References

  • Renascience Pharma Ltd. Summary of Product Characteristics (SPC). Renoxitin 1g Powder for solution for Injection or Infusion. [on-line] Last revision of the text: 14/5/25. Accessed via www.medicines.org.uk. Accessed 5/9/25
  • The Renal Drug Database. Cefoxitin Sodium. [online]. Last updated 31/10/23. Accessed via https://renaldrugdatabase.com Accessed 5/9/25

  • BNF online accessed via www.medicinescomplete.com Accessed 5/9/25

Editorial Information

Next review date: 01 Sept 2028